Why Isn't Platelet Count in the IPSET-Thrombosis Risk Score?

It is one of the most conceptually difficult aspects of an Essential Thrombocythemia (ET) diagnosis: a key diagnostic finding is a sustained high platelet count, yet your doctor might tell you that your risk of a blood clot is “low.” Platelet count is not included in the IPSET-Thrombosis risk score because available observational studies have not shown that the absolute number of platelets in your blood is a reliable predictor of your risk of having a clot ^[1][2]. However, a very high platelet count (a condition called extreme thrombocytosis, typically defined as platelets >1,000 × 10^9/L or >1 million/µL) can add a risk of bleeding ^[3][4]. It is important to know that this added bleeding risk does not eliminate your clot risk—both risks can coexist ^[5].

What Determines Clot Risk in ET?

Instead of simply counting platelets, the IPSET-Thrombosis score (International Prognostic Score for Thrombosis in ET) evaluates variables that have been proven to drive blood clots. The original score included cardiovascular risk factors, but the revised score focuses strictly on three variables to estimate risk ^[6]:

• Age over 60: Getting older naturally changes blood vessels and increases baseline clot risk ^[7][6].
• Prior history of thrombosis: Having had a blood clot in the past is one of the strongest predictors of having another one ^[7][6].
• JAK2 V617F mutation status: Patients who test positive for the JAK2 V617F mutation generally have a higher risk of both arterial clots (like a heart attack or stroke) and venous clots (like a deep vein thrombosis or pulmonary embolism) compared to those with CALR mutations ^[8].

The Revised IPSET-Thrombosis Categories

Doctors use these three factors to place patients into one of four risk categories ^[6]:

Note: A “very low” or “low” score is a statistical estimate of thrombosis risk; it is not a guarantee that you will never have a clot. Furthermore, even though cardiovascular factors (like high blood pressure, diabetes, smoking, and high cholesterol) are not in this revised score, doctors still consider your cardiovascular health to be a critical part of your overall clot risk and will manage it actively ^[9][10].

Why Don’t More Platelets Mean More Clots?

It seems logical that more platelets would automatically mean a proportionally higher chance of a clot. But in ET, the driver mutations that cause the disease change how the blood cells behave and create a systemic state of inflammation in the body. It is this underlying disease biology that drives clots, rather than the sheer volume of platelets ^[8][11].

When researchers analyze large groups of ET patients, they find that patients with extreme thrombocytosis (>1,000 × 10^9/L) do not have a meaningfully higher rate of blood clots than patients with moderately elevated platelets ^[1].

The Bleeding Paradox: Acquired von Willebrand Syndrome

There is a specific reason why a platelet count over 1 million/µL changes how doctors manage your care. When you have a very high number of circulating platelets, they can bind to and use up a crucial blood protein called von Willebrand factor, which acts like glue to help platelets stick together when you get a cut ^[3][4].

When too much of this protein is consumed, it leads to a condition called Acquired von Willebrand Syndrome (AVWS) ^[3]. This means your blood struggles to clot properly, increasing your risk of abnormal bleeding (like heavy periods, nosebleeds, or bruising) ^[12][5].

Because of this bleeding risk, clinicians commonly assess for AVWS in the setting of extreme thrombocytosis by ordering specific blood tests (like von Willebrand factor activity and antigen levels) ^[13]. However, AVWS can sometimes occur even if platelets are under 1 million, and not everyone over 1 million develops clinically important AVWS ^[5].

Safety Warning: Do Not Change Aspirin on Your Own
Daily aspirin is often used to prevent clots in ET, but if you have AVWS, aspirin can worsen your bleeding risk. Whether you should start, stop, or continue aspirin depends on your individualized risk of both clotting and bleeding ^[14][12]. Never start or stop aspirin without your hematologist’s advice. Seek urgent medical care for symptoms of a clot (sudden weakness, speech trouble, chest pain, sudden shortness of breath) or severe bleeding (uncontrolled bleeding, black stools, vomiting blood).

What This Means for Your Treatment Goals

This clinical reality is why it is entirely possible to have a platelet count of 1.2 million/µL but still be categorized as “very low risk” or “low risk” for thrombosis. If you are under 60, have never had a clot, and lack the JAK2 V617F mutation, your statistical risk of a clot remains relatively low despite the high lab value ^[15].

Treatment goals in ET are highly individualized. While your doctor’s plan will focus on managing your actual thrombosis risk factors rather than simply forcing the platelet number into a “normal” range ^[16][1], a very high platelet count cannot be completely ignored. Your count can still influence decisions about cytoreductive therapy (medications that lower blood counts) if you develop bleeding, significant symptoms, or are planning a pregnancy ^[1][17].